Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (25939)
All Articles published online
|
Featured Article
|
Publishing Process of This Article
|
Dec 26, 2015 (publication date) through Feb 8, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Cardiology
ISSN
1949-8462
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Schulte C, Westermann D, Blankenberg S, Zeller T. Diagnostic and prognostic value of circulating microRNAs in heart failure with preserved and reduced ejection fraction. World J Cardiol 2015; 7(12): 843-860 [PMID: 26730290 DOI: 10.4330/wjc.v7.i12.843] |
|---|---|
| URL: | https://www.wjgnet.com/1949-8462/full/v7/i12/843.htm |
| Number | Citing Articles |
| 1 |
Masood Abu-Halima, Eckart Meese, Andreas Keller, Hashim Abdul-Khaliq, Tanja Rädle-Hurst. Analysis of circulating microRNAs in patients with repaired Tetralogy of Fallot with and without heart failure. Journal of Translational Medicine 2017; 15(1) doi: 10.1186/s12967-017-1255-z
|
| 2 |
Fani Chatzopoulou, Konstantinos A. Kyritsis, Christos I. Papagiannopoulos, Eleftheria Galatou, Nikolaos Mittas, Nikoleta F. Theodoroula, Andreas S. Papazoglou, Efstratios Karagiannidis, Maria Chatzidimitriou, Anna Papa, Georgios Sianos, Lefteris Angelis, Dimitrios Chatzidimitriou, Ioannis S. Vizirianakis. Dissecting miRNA–Gene Networks to Map Clinical Utility Roads of Pharmacogenomics-Guided Therapeutic Decisions in Cardiovascular Precision Medicine. Cells 2022; 11(4): 607 doi: 10.3390/cells11040607
|
| 3 |
Janika Viereck, Thomas Thum. Circulating Noncoding RNAs as Biomarkers of Cardiovascular Disease and Injury. Circulation Research 2017; 120(2): 381 doi: 10.1161/CIRCRESAHA.116.308434
|
| 4 |
Yuanyuan Zhao, Dunfeng Du, Shanshan Chen, Zhishui Chen, Jiajia Zhao. New Insights into the Functions of MicroRNAs in Cardiac Fibrosis: From Mechanisms to Therapeutic Strategies. Genes 2022; 13(8): 1390 doi: 10.3390/genes13081390
|
| 5 |
Jemima Osekafore Adewuyi, Roshan Patel, Riccardo Abbasciano, Gerry P. McCann, Gavin Murphy, Marcin J. Woźniak, Anvesha Singh. A systematic review of micro‐RNAs in aortic stenosis and cardiac fibrosis. Clinical and Translational Science 2022; 15(8): 1809 doi: 10.1111/cts.13303
|
| 6 |
Bhuvnesh Rai, Pramod Kumar Maurya, Medha Srivastava, Prabhakar Mishra, Mehar Hasan Asif, Swasti Tiwari. An In-Silico Approach to Identify Therapeutic Target and Markers Associated with Diabetic Nephropathy. Current Diabetes Reviews 2025; 21(2) doi: 10.2174/1573399819666220610191935
|
| 7 |
S Yang, C Fu, R Xu, Z Xun, X Zhao, R Fang. Serum microRNA-302b: the novel biomarker for diagnosis of acute myocardial infarction. British Journal of Biomedical Science 2017; 74(4): 214 doi: 10.1080/09674845.2017.1333665
|
| 8 |
James M. Henderson, Floriana M. Farina, Donato Santovito. miRNAs, Human Health and Diseases. Epigenetics and Human Health 2024; 13: 241 doi: 10.1007/978-3-031-64788-8_9
|
| 9 |
Shan-shan Zhou, Jing-peng Jin, Ji-qun Wang, Zhi-guo Zhang, Jonathan H Freedman, Yang Zheng, Lu Cai. miRNAS in cardiovascular diseases: potential biomarkers, therapeutic targets and challenges. Acta Pharmacologica Sinica 2018; 39(7): 1073 doi: 10.1038/aps.2018.30
|
| 10 |
Christian Schulte, Tanja Zeller. Biomarkers in primary prevention. Herz 2020; 45(1): 10 doi: 10.1007/s00059-019-04874-2
|
| 11 |
Dimitris E. Messinis, Ioannis N. Melas, Junguk Hur, Navya Varshney, Leonidas G. Alexopoulos, Jane P.F. Bai. Translational Systems Pharmacology‐Based Predictive Assessment of Drug‐Induced Cardiomyopathy. CPT: Pharmacometrics & Systems Pharmacology 2018; 7(3): 166 doi: 10.1002/psp4.12272
|
| 12 |
Michele Correale, Ilenia Monaco, Natale Daniele Brunetti, Matteo Di Biase, Marco Metra, Savina Nodari, Javed Butler, Mihi Gheorghiade. Redefining biomarkers in heart failure. Heart Failure Reviews 2018; 23(2): 237 doi: 10.1007/s10741-018-9683-2
|
| 13 |
Radka Sigutova, Lukas Evin, David Stejskal, Vera Ploticova, Zdenek Svagera. Specific microRNAs and heart failure: time for the next step toward application?. Biomedical Papers 2022; 166(4): 359 doi: 10.5507/bp.2022.028
|
| 14 |
Carolina Soler-Botija, Carolina Gálvez-Montón, Antoni Bayés-Genís. Epigenetic Biomarkers in Cardiovascular Diseases. Frontiers in Genetics 2019; 10 doi: 10.3389/fgene.2019.00950
|
| 15 |
Antonino Tuttolomondo, Irene Simonetta, Antonio Pinto. MicroRNA and receptor mediated signaling pathways as potential therapeutic targets in heart failure. Expert Opinion on Therapeutic Targets 2016; 20(11): 1287 doi: 10.1080/14728222.2016.1212017
|
| 16 |
Y Gao, X Liang, Z Tian, Y Ma, C Sun. Betalain exerts cardioprotective and anti-inflammatory effects against the experimental model of heart failure. Human & Experimental Toxicology 2021; 40(12_suppl): S16 doi: 10.1177/09603271211027933
|
| 17 |
Xia He, Jun Ji, Tao Wang, Ming-Bang Wang, Xiao-Ling Chen. Upregulation of Circulating miR-195-3p in Heart Failure. Cardiology 2017; 138(2): 107 doi: 10.1159/000476029
|
| 18 |
Desh Deepak Singh, Youngsun Kim, Seung Ah Choi, Ihn Han, Dharmendra Kumar Yadav. Clinical Significance of MicroRNAs, Long Non-Coding RNAs, and CircRNAs in Cardiovascular Diseases. Cells 2023; 12(12): 1629 doi: 10.3390/cells12121629
|
| 19 |
Maria E. Marketou, Joanna Kontaraki, Alexandros Patrianakos, Emmanuel Kanoupakis, Anthoula Plevritaki, Hercules Mavrakis, Eleutherios Kallergis, Emmanuel Koutalas, Ioannis Anastasiou, Gregory Chlouverakis, Fragiskos Parthenakis. Long-term prognostic value of myocardin expression levels in non-ischemic dilated cardiomyopathy. Heart and Vessels 2021; 36(12): 1841 doi: 10.1007/s00380-021-01869-0
|
| 20 |
Apurva Shrivastava, Tina Haase, Tanja Zeller, Christian Schulte. Biomarkers for Heart Failure Prognosis: Proteins, Genetic Scores and Non-coding RNAs. Frontiers in Cardiovascular Medicine 2020; 7 doi: 10.3389/fcvm.2020.601364
|
| 21 |
ANRIL's Epigenetic Regulation and Its Implications for Cardiovascular Disorders. Journal of Biochemical and Molecular Toxicology 2024; 38(12) doi: 10.1002/jbt.70076
|
| 22 |
Wei Zhou, Ming-Yu Fan, You-Xiu Wei, Song Huang, Jing-You Chen, Ping Liu. The expression of MYH9 in osteosarcoma and its effect on the migration and invasion abilities of tumor cell. Asian Pacific Journal of Tropical Medicine 2016; 9(6): 597 doi: 10.1016/j.apjtm.2016.04.011
|
| 23 |
Christian Schulte, Mahir Karakas, Tanja Zeller. microRNAs in cardiovascular disease – clinical application. Clinical Chemistry and Laboratory Medicine (CCLM) 2017; 55(5) doi: 10.1515/cclm-2016-0576
|
| 24 |
Maria Dorobantu, Nicoleta-Monica Popa-Fotea, Mihaela Popa, Iulia Rusu, Miruna Mihaela Micheu. Pursuing meaningful end-points for stem cell therapy assessment in ischemic cardiac disease. World Journal of Stem Cells 2017; 9(12): 203-218 doi: 10.4252/wjsc.v9.i12.203
|